Chemotherapy Plus Local Treatment in the Management of Intraocular Retinoblastoma

Murphree, A. Linn

doi:10.1001/archopht.1996.01100140548005

Cited by 424 publications

(251 citation statements)

References 24 publications

Supporting

Mentioning

225

Contrasting

Unclassified

Order By: Relevance

“…29 It has evolved to be an important measure in the initial management of retinoblastoma. [30][31][32][33][34] The chemotherapeutic agents vary depending on the preference of the pediatric oncologist. We presently use carboplatin, etoposide, and vincristine (Table 3).…”

Section: Chemoreductionmentioning

confidence: 99%

Diagnosis and Management of Retinoblastoma

2004

View full text Add to dashboard Cite

show abstract

Section: Chemoreductionmentioning

confidence: 99%

Diagnosis and Management of Retinoblastoma

2004

View full text Add to dashboard Cite

show abstract

“…1,2 Numerous conservative treatment modalities have been published: cryoapplication, thermotherapy alone or combined with systemic chemotherapy, plaque radiotherapy, or even exclusive chemotherapy. [3][4][5][6][7][8][9][10][11][12] More recently, periocular, intraarterial, and intravitreal administration of chemotherapy have been used and are still under evaluation. These last modalities were developed during the study period.…”

Section: Introductionmentioning

confidence: 99%

Conservative treatment of retinoblastoma: a prospective phase II randomized trial of neoadjuvant chemotherapy followed by local treatments and chemothermotherapy

Rouic

Aerts

Hajage

et al. 2015

Eye

View full text Add to dashboard Cite

Purpose Intraocular retinoblastoma treatments often combine chemotherapy and focal treatments. A first prospective protocol of conservative treatments in our institution showed the efficacy of the use of two courses of chemoreduction with etoposide and carboplatin, followed by chemothermotherapy using carboplatin as a single agent and diode laser. In order to decrease the possible longterm toxicity of chemotherapy due to etoposide, a randomized neoadjuvant phase II protocol was conducted using vincristinecarboplatin vs etoposide-carboplatin. Patients and methods The study was proposed when initial tumor characteristics did not allow front-line local treatments. Patients included in this phase II noncomparative randomized study of neoadjuvant chemotherapy received vincristin-carboplatin (new arm) vs etoposide-carboplatin (our reference arm). They were subsequently treated by local treatments and chemothermotherapy. Primary end point was the need for secondary enucleation or external beam radiotherapy (EBRT) not exceeding 40% at 2 years. Results A total of 65 eyes in 55 children were included in the study (May 2004 to August 2009. Of these, 32 eyes (27 children) were treated in the arm etoposide-carboplatin and 33 eyes (28 children) in the arm vincristin-carboplatin. At 2 years after treatment, 23/33 (69.7%) eyes were treated and salvaged without EBRT or enucleation in the arm vincristin-carboplatin and 26/32 (81.2%) in the arm etoposide-carboplatin. Conclusion Even if the two treatment arms could be considered as sufficiently active according to the study decision rules, neoadjuvant chemotherapy by two cycles of vincristine-carboplatin followed by chemothermotherapy appear to offer less optimal local control than the etoposidecarboplatin combination.

show abstract

“…This approach offers globe salvage for approximately 85% of eyes classified as Reese-Ellsworth groups I to IV, but it is less successful for group V because globe salvage is achieved in only 47% of eyes. 3 Previous publications on the subject of chemoreduction have addressed various issues, some of which include tumor control with chemotherapy alone, 4,5 tumor control with chemotherapy and focal consolidation, [6][7][8][9][10] and risks for failure with need to resort to enucleation or external beam radiotherapy. 3 Chemotherapy alone has been found to control only 8% of eyes with retinoblastoma in various stages, on account of problems with tumor and related seed progression and recurrence.…”

Section: Introductionmentioning

confidence: 99%